The TakeAim Lymphoma Phase 1/2 study is investigating emavusertib as monotherapy and in combination with ibrutinib in patients with R/R hematologic malignancies.
The combination appeared to be well tolerated, with no dose-limiting toxicities (DLTs) at 200mg of emavusertib.
Two DLTs were observed at 300mg (stomatitis and syncope).
8 of 9 evaluable patients experienced a reduction in tumor burden.
The TakeAim Leukemia study is a Phase 1/2 study examining emavusertib use as monotherapy and in combination with azacitidine or venetoclax in patients with R/R AML or high-risk MDS.
Emavusertib was well-tolerated across multiple dose levels, and no dose-limiting myelosuppression was observed.
In patients with spliceosome-mutated R/R AML, CR/CRh rate of 40% (2 out of 5 patients) (CRh=complete response with partial hematologic recovery).
Consistent tumor burden reduction was observed. 4 out of 5 patients achieved blast reduction, three by ≥ 50%.
In patients with spliceosome-mutated R/R MDS, the objective response rate was 57%.
In patients with FLT3-mutated R/R AML, the CR rate was 33%.
Price Action: CRIS shares are up 14.9% at $1.08 during the premarket session on the last check Monday.
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.